Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona, USA.
University of Arizona, College of Medicine-Phoenix, Phoenix, Arizona, USA.
Pediatr Blood Cancer. 2025 Jan;72(1):e31372. doi: 10.1002/pbc.31372. Epub 2024 Oct 16.
Vomiting is a common and distressing acute side effect of chemotherapy, negatively impacting quality of life, nutritional status, and the ability of patients to tolerate further treatment. Standardized guidelines have been developed to improve control of nausea and vomiting. We aimed to determine the benefit of adherence to clinical practice guidelines (CPGs) on complete control of acute chemotherapy-induced vomiting in newly diagnosed pediatric patients with cancer.
An electronic dashboard of pediatric patients newly diagnosed with cancer at Phoenix Children's Hospital between August 2019 and January 2021 and receiving their first cycle of chemotherapy was utilized to monitor chemotherapy regimen, antiemetic medications, and vomiting episodes. Blocks were classified as guideline-inconsistent, guideline-consistent, or guideline-consistent PLUS if additional prophylactic antiemetic medications were utilized. We identified patients with complete control of vomiting, defined as no vomiting and no additional antiemetics needed.
Among 136 patients, 29% received guideline-inconsistent care, 37% received guideline-consistent care, and 34% received guideline-consistent PLUS care. Overall, 48% of patients achieved complete control of vomiting. Older patients (p < 0.0001) and those receiving higher emetogenicity chemotherapy (p = 0.0003) were more likely to receive guideline-consistent or guideline-consistent PLUS therapy. With guideline-consistent and -consistent PLUS grouped together, the diagnosis was also associated with improved adherence to CPGs (p = 0.022). Multivariate analysis showed that patients more likely to receive guideline-consistent prophylaxis were of older age (OR 1.11, p = 0.016) and solid tumor patients (OR 5.59, p = 0.028).
Despite high rates of CPG adherence, complete control of vomiting remains suboptimal, which highlights the need for novel and/or risk-adapted therapies.
呕吐是化疗常见且令人痛苦的急性副作用,会降低生活质量、营养状况,并影响患者对进一步治疗的耐受能力。已制定了标准化指南来改善恶心和呕吐的控制。我们旨在确定遵循临床实践指南(CPG)对控制新诊断的癌症患儿急性化疗诱导性呕吐的完全控制是否有益。
利用凤凰城儿童医院 2019 年 8 月至 2021 年 1 月新诊断为癌症的儿科患者的电子病历仪表盘,监测化疗方案、止吐药物和呕吐发作。根据指南是否一致,将块分为不一致、一致或一致加用,如使用了额外的预防用止吐药物。我们确定了呕吐完全控制的患者,定义为无呕吐且无需额外使用止吐药物。
在 136 名患者中,29%接受了不一致的治疗,37%接受了一致的治疗,34%接受了一致加用的治疗。总体而言,48%的患者实现了呕吐完全控制。年龄较大的患者(p<0.0001)和接受更高致吐性化疗的患者(p=0.0003)更可能接受一致或一致加用的治疗。将一致和一致加用的治疗方案合并在一起,诊断也与 CPG 更高的依从性相关(p=0.022)。多变量分析显示,更可能接受一致预防的患者年龄较大(OR 1.11,p=0.016)且为实体瘤患者(OR 5.59,p=0.028)。
尽管 CPG 的遵循率很高,但呕吐的完全控制仍然不理想,这突出了需要新的和/或风险适应的治疗方法。